The mucoadhesive and gastroretentive properties of hydrophobin-coated porous silicon nanoparticle oral drug delivery systems.

Authors:
Address: Laboratory of Radiochemistry, Department of Chemistry, University of Helsinki, FI-00014, Finland. mirkka.sarparanta@helsinki.fi
Journal:


Publication:

abstract

Impediments to intestinal absorption, such as poor solubility and instability in The variable conditions of the gastrointestinal (GI) tract plague many of the current drugs restricting their oral bioavailability. Particulate drug delivery systems hold great promise in solving these problems, but their effectiveness might be limited by their often rapid transit through the GI tract. Here we describe a bioadhesive oral drug delivery system based on thermally-hydrocarbonized porous silicon (THCPSi) functionalized with a self-assembled amphiphilic protein coating consisting of a class II hydrophobin (HFBII) from Trichoderma reesei. The HFBII-THCPSi nanoparticles were found to be non-cytotoxic and mucoadhesive in AGS cells, prompting their use in a biodistribution study in rats after oral administration. The passage of HFBII-THCPSi nanoparticles in the rat GI tract was significantly slower than that of uncoated THCPSi, and the nanoparticles were retained in stomach by gastric mucoadhesion up to 3 h after administration. Upon entry to the small intestine, the mucoadhesive properties were lost, resulting in the rapid transit of the nanoparticles through the remainder of the GI tract. The gastroretentive drug delivery system with a dual function presented here is a viable alternative for improving drug bioavailability in the oral route.

Copyright © 2012 Elsevier Ltd. All rights reserved.



Related Articles
Intravenous delivery of hydrophobin-functionalized porous silicon nanoparticles: stability, plasma protein adsorption and biodistribution.
Mol Pharm. 2012
Intravenous delivery of hydrophobin-functionalized porous silicon nanoparticles: stability, plasma protein adsorption and biodistribution.
Sarparanta M, Bimbo LM, Rytkönen J, Mäkilä E, Laaksonen TJ, Laaksonen P, Nyman M, Salonen J, Linder MB, Hirvonen J, et al. Mol Pharm. 2012 Mar 5; 9(3):654-63. Epub 2012 Feb 1.
Cellular interactions of surface modified nanoporous silicon particles.
Nanoscale. 2012
Cellular interactions of surface modified nanoporous silicon particles.
Bimbo LM, Sarparanta M, Mäkilä E, Laaksonen T, Laaksonen P, Salonen J, Linder MB, Hirvonen J, Airaksinen AJ, Santos HA. Nanoscale. 2012 May 21; 4(10):3184-92. Epub 2012 Apr 16.
Biocompatibility of thermally hydrocarbonized porous silicon nanoparticles and their biodistribution in rats.
ACS Nano. 2010
Biocompatibility of thermally hydrocarbonized porous silicon nanoparticles and their biodistribution in rats.
Bimbo LM, Sarparanta M, Santos HA, Airaksinen AJ, Mäkilä E, Laaksonen T, Peltonen L, Lehto VP, Hirvonen J, Salonen J. ACS Nano. 2010 Jun 22; 4(6):3023-32.
Review Engineering strategies to enhance nanoparticle-mediated oral delivery.
J Biomater Sci Polym Ed. 2008
Review Engineering strategies to enhance nanoparticle-mediated oral delivery.
Yamanaka YJ, Leong KW. J Biomater Sci Polym Ed. 2008; 19(12):1549-70.
Review Pharmaceutical approaches to colon targeted drug delivery systems.
J Pharm Pharm Sci. 2003
Review Pharmaceutical approaches to colon targeted drug delivery systems.
Chourasia MK, Jain SK. J Pharm Pharm Sci. 2003 Jan-Apr; 6(1):33-66.

To top Home


Show map | Diseases | Vaccination | Chronic disease | Medicine | Pregnancy | Heat & Sunburn | Cold | Security | Useful tips | Faq | News

TraveldoctorOnline 2001 • Disclaimer webmaster

The contents within traveldoctoronline are presented only for informational purposes and cannot substitute for professional health care or any other medical treatment.All users of this website with health problems should be oblige always to consult their medical doctor before starting any treatment.